US 12,129,473 B2
Synthetic cannabinoid compounds for treatment of pain and anxiety
Jonnie R. Williams, Sarasota, FL (US)
Assigned to TNF Pharmaceuticals, Inc., Baltimore, MD (US)
Filed by TNF Pharmaceuticals, Inc., Baltimore, MD (US)
Filed on Feb. 20, 2023, as Appl. No. 18/111,822.
Application 17/383,119 is a division of application No. 16/612,472, granted, now 11,085,047, issued on Aug. 10, 2021, previously published as PCT/US2019/017433, filed on Feb. 11, 2019.
Application 18/111,822 is a continuation of application No. 17/383,119, filed on Jul. 22, 2021, granted, now 11,629,355.
Claims priority of provisional application 62/632,448, filed on Feb. 20, 2018.
Prior Publication US 2023/0212597 A1, Jul. 6, 2023
Int. Cl. A61K 31/352 (2006.01); A61K 36/185 (2006.01); C12N 15/82 (2006.01)
CPC C12N 15/8243 (2013.01) [A61K 31/352 (2013.01); A61K 36/185 (2013.01); C12N 15/8257 (2013.01)] 11 Claims
 
1. A method of treating pain comprising administering to an individual in need thereof a pharmaceutical composition comprising a compound having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.